| HSP90 | Heat Shock Protein 90 |
| HER2 | Human Epidermal Growth Factor Receptor 2 |
| ADC | Antibody–drug conjugates |
| T-DM1 | Trastuzumab emtansine |
| T-Dxd | Trastuzumab deruxtecan |
| TKI | Tyrosine kinase inhibitors |
| Trast | Trastuzumab |
| Doc | Docetaxel |
| Pert | Pertuzumab |
| Combo | Combination |
| PFS | Progression-free survival |
| OS | Overall survival |
| ATCC | American Type Culture Collection |
| DMEM | Dulbecco’s Modified Eagle’s Medium |
| FBS | Fetal bovine serum |
| EV | Empty Vector |
| ER | Estrogen Receptor |
| PgR | Progesteron Receptor |
| IHC | Immunohistochemistry |
| FISH | Fluorescence In Situ Hybridization |
| CT | Computer Tomography |
| PET | Positron Emission Tomography |
| HRs | Hazard ratios |
| HT | Hormonal Treatment |